MedTrace Logo

A Bioequivalence Study of Tobradex AF

NCT00362895 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 995

Last updated 2012-03-05

No results posted yet for this study

Summary

The purpose of the study is to determine the amount of study medication that moves from the front of the eye into the fluid at the front of the inside of the eye.

Conditions

  • Cataract

Interventions

DRUG

Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension

One drop in the study eye, single dose

DRUG

Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)

One drop in the study eye, single dose

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2006-08-31
Completion
2006-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00362895 on ClinicalTrials.gov